The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

ProteoSys AG offers biotechnology research services. It provides solutions for the drug development process focusing on target system discovery, target validation, modes of action, studies of side effects and toxicology. The company was founded by Andr�� Schrattenholz and Helmut Matthies in 2000 and is headquartered in Mainz, Germany.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

Sami-Sabinsa Group Ltd. manufactures & markets nutraceuticals, herbal extracts, chemicals and active pharmaceutical ingredients. It also offers probiotics, enzymes, spice extracts, minerals and oils. The company was founded in 1991 by Muhammed Majeed and is headquartered in Bangalore, India.

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

Salix Pharmaceuticals Ltd. develops and commercializes prescription drugs and medical devices used in the treatment of gastrointestinal diseases, endocrinology, hepatology, colorectal surgery, and internal medicine. It offers Anusol, Apriso, Colazal, Deflux, Diuril, Fenoglide, MoviPrep, Pepcid, Solesta, and Zegerid. The company was founded by randy W. Hamilton and Lorin K. Johnson in1989 and is headquartered in Bridgewater, NJ.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. They are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. Its products include Adagloxad Simolenin, which is a late-stage novel active immune-oncology Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The company was founded by Michael N. Chang on April 29, 2002 and is headquartered in Taipei, Taiwan.